about
Oncogenic Intra-p53 Family Member Interactions in Human CancersPhosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytesHMGA1 and HMGA2 protein expression in mouse spermatogenesisThe cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expressionMicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of functionCynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.PML Surfs into HIPPO Tumor Suppressor Pathway.Gender, mutant p53 and PML: a growing "affaire" in tumor suppression and oncogenesis.ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence.YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation.Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.Hippo and rassf1a Pathways: A Growing AffairMutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.The MAPK pathway triggers activation of Nek2 during chromosome condensation in mouse spermatocytes.The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts.Prolin-rich tyrosine kinase 2 (PYK2) expression and localization in mouse testis.Meiotic progression of isolated mouse spermatocytes under simulated microgravity.A combined atomic force microscopy imaging and docking study to investigate the complex between p53 DNA binding domain and Azurin.Promyelocytic leukemia protein is required for gain of function by mutant p53.Analysis of the gene expression profile of mouse male meiotic germ cells.New therapeutic strategies to treat human cancers expressing mutant p53 proteins.Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.Interaction of mutant p53 with p73: A Surface Plasmon Resonance and Atomic Force Spectroscopy studyArenavirus as a potential etiological agent of odontogenic tumours in humansThe miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell CarcinomasThe Impact of Mutant p53 in the Non-Coding RNA WorldTargeting mutant p53 in cancer: the latest insightsWild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease
P50
Q26749382-1E8D0336-6B74-4AE1-A25B-0ED1166C8066Q28511974-8EA7F46E-53EA-4577-8CA4-66AB6B683D11Q28592453-808A8698-C893-4526-9BBE-D43A49591EFAQ35562669-D3A0047F-C424-4CC5-BB65-C5E664EECF67Q35742357-2505D3A7-2CEC-4F42-B2CA-49C3DF2EF20AQ35965859-7B213A29-CF9F-42AA-8B4B-34E01D2BDA39Q36228527-9DBA01AA-3AE5-458F-AF4C-1C3379B2627CQ36647912-98EC5B19-F969-4D55-BDAE-EB90CBA75596Q37075885-E40CDBED-45D1-446F-8AD9-2A737BCB4AB0Q37219985-3236C11D-8EEC-492F-B6D9-D07EC2DCBE24Q37623308-57AF651C-4E4A-4F71-8CC3-5FDC4832B02CQ37706584-0FD5C7FC-6670-452E-987F-09A5681A3BCEQ38357857-3D592B17-8299-46B4-9CDA-DD2CC26AF88DQ38948274-8B6F95BB-5B31-443A-8DBD-94CC85E3C759Q39166823-9B4ABA4C-D264-4648-96C0-99D3E1E318F6Q39434450-4B62B0A9-2FBE-414B-96BB-FC3674A10A1AQ39598993-3A560B00-3C01-430A-8762-60B6FC82B55AQ39667788-BF8CFF56-DBD3-4174-AE18-CE64358D9181Q39791018-20EF48FD-1D34-495A-949F-700EDB95754BQ42240973-437BFB79-C374-4C54-A438-42822668FD45Q42282841-39DF6CF2-F187-47AB-A763-241728F99F94Q42511555-AD878702-8A28-424A-843B-F5107DEF6174Q42724753-FE38E168-EEFC-4351-8731-1FBB66064FC6Q43939969-A6F1F87D-8749-4F4B-A939-F81047390FF9Q44078613-9E4631B6-7D43-419D-B3EB-7515F45E7328Q44464228-A6414CD0-507B-419D-B1D6-A7642FBAA9E9Q44962199-65EE5FC1-8385-4DAC-8924-51D2E32EEEC1Q45916192-391C0A55-D891-4BEC-A21B-11D1DF009FF1Q47677481-43275B15-CAC7-4163-AF32-3C21F7E0468AQ47850508-1EBD304A-690C-4259-9041-560FA5039B27Q49962911-6AD5E633-571D-4263-8C6F-5828743426EAQ51075761-476DC9BB-DD4A-419B-AE3C-4622FB553DBCQ51353586-08C0212B-E6F9-4814-919F-0C9F8691B82FQ51416797-0450EB6F-B487-4089-9763-E0087C92E343Q61190995-4AE77535-2792-4A81-A968-D96713D2C552Q89635555-DD0FE933-D2DC-4EE2-B4A2-124CF045787EQ90080210-8EBE1B10-8231-4384-89D0-0C93B05A67D4Q90599087-2A399B01-3995-47B8-9427-CE09ABE5BD4EQ91660555-9DC7235A-01B4-4011-9071-5FB9F691DFBFQ92190137-95B49612-1804-4A6D-95BD-F5D45D76EF5F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Di Agostino
@ast
Silvia Di Agostino
@en
Silvia Di Agostino
@es
Silvia Di Agostino
@nl
Silvia Di Agostino
@sl
type
label
Silvia Di Agostino
@ast
Silvia Di Agostino
@en
Silvia Di Agostino
@es
Silvia Di Agostino
@nl
Silvia Di Agostino
@sl
prefLabel
Silvia Di Agostino
@ast
Silvia Di Agostino
@en
Silvia Di Agostino
@es
Silvia Di Agostino
@nl
Silvia Di Agostino
@sl
P106
P21
P31
P496
0000-0003-3730-1125